winner 777 login
winner 777 login
《TAIPEI TIMES》Minister back after clinching German, Czech tech pacts
Julian Alvarez and second-half substitute Angel Correa scored twice as Atletico Madrid cruised to an easy 6-0 win at struggling Sparta Prague in the Champions League on Tuesday. The win leaves Diego Simeone’s Rojiblancos on nine points from five games in the competition, while Sparta have four. “Each win makes you happy, especially when the team plays like this throughout the game and scores like today,” Atletico coach Simeone told reporters in the Czech capital. “We really did well today,” he added, hailing his team for playing “with high intensity and speed”. Alvarez opened the scoring 15 minutes into the game as he was brought down just outside the box and then curled a free-kick into the top corner of Peter Vindahl’s goal. Marcos Llorente made it 2-0 two minutes from half-time as he chipped the ball towards the goal and Vindahl let it in, visibly fooled by striker Alexander Sorloth’s attempt at a glancing header. Alvarez fired in his second from close range on 59 minutes after a give-and-go with Giuliano Simeone, the coach’s son. Second-half substitute Antoine Griezmann made it 4-0 on 70 minutes with a low shot inside the box following a one-two with Llorente. Correa rounded off the score with two goals in the final five minutes, first poking in a pass from fellow substitute Samuel Lino and then finishing neatly after a mazy run through the static Sparta defence. – ‘All goals count’ – “The team understood what I want from them from the beginning to the end including the substitutes who played really well as soon as they entered the pitch,” said Diego Simeone. “All goals count. We tried to score as many as possible because it helps with this new format of the Champions League. “We are always aware the game has 90 minutes and we have to play as best we can,” he added. The 54-year-old Argentinian made six changes following Atletico’s 2-1 win over Alaves in La Liga on Saturday, his 700th game across all competitions in charge of the team. But there was little doubt about the outcome as Sparta only managed a single weak shot on goal through Kaan Kairinen in the opening minute. Atletico controlled the game, tirelessly testing the wobbly defence of the reigning Czech champions who have now only won two of their last 12 games in all competitions. Vindahl spared Sparta blushes on several occasions as he stopped close-range efforts from Rodrigo De Paul and Sorloth in the first half and Giuliano Simeone after the break. Atletico took a second straight away win in the Champions League at Sparta after stunning Paris Saint-Germain 2-1 earlier this month. With three games to play in the new-format league phase, they next face underdogs Slovan Bratislava at home on December 10. AFP
AH Real Deal: The TCL 50-inch Q5 TV is now $200 off
The mandate in Jharkhand has, yet again, caused a roadblock for the Bharatiya Janata Party (BJP). The key elements that decided the fate of the election can be summed up to the tenacity and the ability of State-level forces to face and respond to all-India intrusions and, second, the tough competition between regional identity-based politics centred around Adivasis vis-à-vis an attempt to draw in Adivasis toward a set of aggressive and all-India concerns that are centred on cultural identity. At the tactical level, the emphatic victory of the Jharkhand Mukti Morcha (JMM)-led alliance was a victory: of effective coalition management and of a campaign that focused on issues that struck a chord with voters. But beyond that, Jharkhand saw a clear competition between two alternative narratives. The JMM-led government was defending its track record in governance and its image of representing tribal interests. The BJP-led alliance sought to present a wider narrative to try and appeal to a wider cross-section and aggressively attack the incumbent government on non-performance and high levels of corruption. Methodology The findings are from the Jharkhand Assembly Election Study 2024 that was conducted by the Lokniti programme of the Centre for the Study of Developing Societies (CSDS), Delhi, between November 12-19, 2024. A total of 3,035 respondents were interviewed across 30 Assembly Constituencies and 150 polling stations of Jharkhand. Using multi-stage random sampling, this procedure ensured that the selected sample was fully representative of the cross-section of voters. The constituencies where the survey was conducted were randomly selected using the probability proportional to size method (adjusting the probability of choosing a particular constituency according to the size of its electorate). Thereafter, five polling stations were selected in each of the sampled constituencies using the systematic random sampling method. Finally, 40 respondents were selected at random using the systematic random sampling method from the electoral rolls of the sampled polling stations. Of these 40, we set a target of 20 interviews per polling station. Once we identified our sample, trained field investigators conducted face-to-face interviews using a pre-designed mobile App. The questionnaire was translated into Hindi. Though the sample is relatively small, the total number of voters interviewed represent the social reality of the voters in Jharkhand, i.e., the sample is truly representative with regard to the social composition of the State. Weights were applied to make corrections for under-representation of any social groups. Weights were also applied based on the actual result. The study was directed by Sanjay Kumar, Suhas Palshikar and Sandeep Shastri. Published - November 27, 2024 01:12 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit Jharkhand Assembly Elections 2024 / Jharkhand
HOUSTON (AP) — The Houston Texans made mistakes in every facet of the game Sunday against the Tennessee Titans to lose for the third time in four games. C.J. Stroud threw two interceptions, the defense gave up multiple big passing plays and Ka′imi Fairbairn missed a 28-yard field goal that would have tied it late in a 32-27 loss . “Just a disappointing loss for us,” coach DeMeco Ryans said. “We didn’t do anything well enough to win this game. Out of all the positives that we did have, there were way too many negatives, too many negative plays.” Jimmie Ward had a 65-yard interception return for a touchdown in the third quarter and the Texans tied a franchise record with eight sacks. Danielle Hunter led the group with a season-high three sacks and Will Anderson Jr. added two in his return after missing two games with an ankle injury. But the offense sputtered for most of the game as Joe Mixon was held to 22 yards on 14 carries. But Ryans refused to blame the offense for the loss. “Our offense did plenty," Ryans said. "They gave us enough points. On defense, we have to be able to stop them.” Chig Okonkwo grabbed a short pass and rumbled 70 yards for a touchdown to put the Titans (3-8) up 30-27 with 91⁄2 minutes remaining. Safety Eric Murray missed a tackle that would have stopped him near midfield. It was the last of three big passing plays the Titans had Sunday. Nick Westbrook-Ikhine got in front of the defense and was wide open for a 38-yard TD catch that made it 10-7 late in the first quarter. Calvin Ridley had a 63-yard reception that set up their next touchdown in the second. “It was just way too many negative plays,” Ryans said. “Defensively, unexplainable explosives for touchdowns. We didn’t play good across the board and that starts with me.” Despite this, the Texans (7-5) had a chance to tie it with less than two minutes remaining, but Fairbairn’s short field-goal attempt sailed wide left. He fell to the ground after the miss before getting up and slamming his helmet on the field. “The most frustrating part about it is out of all the bad things that happened, we still had a chance to finish the game,” Ryans said. “Everything that could go wrong, it went wrong. We still had a chance there to tie it up and finish the game, and we didn’t.” The Texans forced a three-and-out, but couldn’t move the ball after that and Harold Landry sacked Stroud in the end zone for a safety to make it 32-27 and allow Tennessee to snap a two-game skid. Stroud threw for 247 yards and two touchdowns, but his two interceptions Sunday give him five combined in the past three games. He now has more interceptions in 12 games this season (nine) than he had in 15 games as a rookie last season (five). “It’s no secret that I haven’t been playing well ... I’ve got to be harder on myself,” he said. “I’m not going to hold my head down. I know I can be a great player, but I’ve got to make better plays.” AP NFL: https://apnews.com/hub/nflManhattan police have obtained a warrant for the arrest of 26-year-old Luigi Nicholas Mangione , suspect in the killing of UnitedHealthcare CEO Brian Thompson . Mangione was arrested at a McDonald’s in Altoona, Pennsylvania, while carrying a gun, mask and writings linking him to the ambush. Mangione is being held without bail in Pennsylvania on charges of possession of an unlicensed firearm, forgery and providing false identification to police. Late Monday, Manhattan prosecutors charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Here's the latest: From wealth and success to murder suspect, the life of Luigi Mangione took a hard turn Luigi Nicholas Mangione, the suspect in the fatal shooting of a healthcare executive in New York City, apparently was living a charmed life: the grandson of a wealthy real estate developer, valedictorian of his elite Baltimore prep school and with degrees from one of the nation’s top private universities. Friends at an exclusive co-living space at the edge of touristy Waikiki in Hawaii where the 26-year-old Mangione once lived widely considered him a “great guy,” and pictures on his social media accounts show a fit, smiling, handsome young man on beaches and at parties. Now, investigators in New York and Pennsylvania are working to piece together why Mangione may have diverged from this path to make the violent and radical decision to gun down UnitedHealthcare CEO Brian Thompson in a brazen attack on a Manhattan street. The killing sparked widespread discussions about corporate greed, unfairness in the medical insurance industry and even inspired folk-hero sentiment toward his killer. ▶ Read more about Luigi Mangione Pennsylvania prosecutor will work with NY officials to return suspect Peter Weeks, the Blair County district attorney, says he’ll work with New York officials to try to return suspect Luigi Mangione there to face charges. Weeks said the New York charges are “more serious” than in Blair County. “We believe their charges take precedent,” Weeks said, promising to do what’s needed to accommodate New York’s prosecution first. Weeks spoke to reporters after a brief hearing at which a defense lawyer said Mangione will fight extradition. The defense asked for a hearing on the issue. In the meantime, Mangione will be detained at a state prison in western Pennsylvania. What New York officials will do to bring Mangione back there Manhattan District Attorney Alvin Bragg’s office said Tuesday it will seek a Governor’s warrant to secure Mangione’s extradition to Manhattan. Under state law, New York Gov. Kathy Hochul can issue a warrant of arrest demanding Mangione’s return to the state. Such a warrant must recite the facts necessary to the validity of its issuance and be sealed with the state seal. It would then be presented to law enforcement in Pennsylvania to expedite Mangione’s return to New York. District attorney says Mangione contesting extradition will create ‘extra hoops’ to jump through But Blair County District Attorney Peter Weeks says it won’t be a substantial barrier to returning Mangione to New York. He noted that defendants contest extradition “all the time,” including in simple retail theft cases. In court, Mangione said he understood his rights Dickey, his defense lawyer, questioned whether the second-degree murder charge filed in New York might be eligible for bail under Pennsylvania law, but prosecutors raised concerns about both public safety and Mangione being a potential flight risk, and the judge denied it. Mangione will continue to be housed at a state prison in Huntingdon. Defense lawyer Thomas Dickey told the court Mangione wants a hearing on the extradition issue He has 14 days to challenge the detention. Prosecutors, meanwhile, have a month to seek a governor’s warrant out of New York. Mangione’s demeanor in court Mangione, wearing an orange jumpsuit, mostly stared straight ahead at the hearing, occasionally consulting papers, rocking in his chair, or looking back at the gallery. At one point, he began to speak to respond to the court discussion, but was quieted by his lawyer. Suspect in the killing of UnitedHealthcare’s CEO is contesting his extradition back to New York Luigi Mangione, 26, has also been denied bail at a brief court hearing in western Pennsylvania. He has 14 days to challenge the bail decision. An account on X that appears to belong to Mangione was still up as of Tuesday That’s with some intervention from owner Elon Musk. The account, which hasn’t posted since June, was briefly suspended by X. But after a user inquired about it in a post Monday, Musk responded “This happened without my knowledge. Looking into it.” The account was later reinstated. Other social media companies such as Meta have removed his accounts. According to X rules, the platform removes “any accounts maintained by individual perpetrators of terrorist, violent extremist, or mass violent attacks, as well as any accounts glorifying the perpetrator(s), or dedicated to sharing manifestos and/or third party links where related content is hosted.” Mangione is not accused of perpetrating a terrorist or mass attack — he has been charged with murder — and his account doesn’t appear to share any writings about the case. Mangione shouted and struggled with officers as he arrived in court He shouted something that was partly unintelligible, but referred to an “insult to the intelligence of the American people.” He’s there for an arraignment on local charges stemming from his arrest Monday. Mangione arrives at court in Pennsylvania He was dressed in an orange jumpsuit as officers led him from a vehicle into the courthouse. Local defense lawyer Thomas Dickey is expected to represent the 26-year-old at a Tuesday afternoon hearing at the Blair County Courthouse. Dickey declined comment before the hearing. Mangione could have the Pennsylvania charges read aloud to him and may be asked to enter a plea. They include possession of an unlicensed firearm, forgery and providing false identification to police. In New York, he was charged late Monday with murder in the death of UnitedHealthcare’s CEO Brian Thompson. Bulletin says Mangione likely motivated by anger toward ‘parasitic’ health insurance companies Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain with corporate greed, said a a law enforcement bulletin obtained by The Associated Press. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, based on a review of the suspect’s hand-written notes and social media postings. He appeared to view the targeted killing of the UnitedHealthcare CEO as a symbolic takedown, asserting in his note that he is the “first to face it with such brutal honesty,” the bulletin said. Mangione called “Unabomber” Ted Kaczynski a “political revolutionary” and may have found inspiration from the man who carried out a series of bombings while railing against modern society and technology, the document said. Police say they found ‘written admissions about the crime’ in Luigi Mangione’s belongings A felony warrant filed in New York cites Altoona Officer Christy Wasser as saying she found the writings along with a semi-automatic pistol and an apparent silencer. The filing echoes earlier statements from NYPD Chief of Detectives Joseph Kenny who said Mangione had a three-page, handwritten document that shows “some ill will toward corporate America.” Mangione is now charged in Pennsylvania with being a fugitive of justice. McDonald’s customer: ‘My one friend thought he looked like the shooter’ A customer at the McDonald’s in Altoona, Pennsylvania, where Mangione was arrested said one of his friends had commented beforehand that the man looked like the suspect wanted for the shooting in New York City. “It started out almost a little bit like a joke, my one friend thought he looked like the shooter,” said the customer, who declined to give his full name, on Tuesday. “It wasn’t really a joke, but we laughed about it,” he added. Manhattan prosecutors have obtained a warrant for Mangione’s arrest The warrant on murder and other charges is a step that could help expedite his extradition from Pennsylvania. In court papers made public Tuesday, a New York City police detective reiterated key findings in the investigation he said tied Mangione to the killing, including surveillance footage and a fake ID he used to check into a Manhattan hostel on Nov. 24. Police officers in Altoona, Pennsylvania, found that ID when they arrested Mangione on Monday. Mangione is being held without bail in Pennsylvania on charges of possession of an unlicensed firearm, forgery and providing false identification to police. Late Monday, Manhattan prosecutors charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Mangione doesn’t yet have a lawyer who can speak on his behalf, court officials said. Pennsylvania authorities release photos of Luigi Mangione at McDonald’s and in cell Images of Mangione released Tuesday by Pennsylvania State Police showed him pulling down his mask in the corner of the McDonald’s while holding what appeared to be hash browns and wearing a winter jacket and ski cap. In another photo from a holding cell, he stood unsmiling with rumpled hair. The suspect’s cousin, a Maryland lawmaker, is postponing a fundraiser Mangione’s cousin, Maryland lawmaker Nino Mangione, announced Tuesday morning that he’s postponing a fundraiser planned later this week at the Hayfields Country Club north of Baltimore, which was purchased by the Mangione family in 1986. “Because of the nature of this terrible situation involving my Cousin I do not believe it is appropriate to hold my fundraising event scheduled for this Thursday at Hayfields,” Nino Mangione said in a social media post. “I want to thank you for your thoughts, prayers, and support. My family and I are heartbroken and ask that you remember the family of Mr. Thompson in your prayers. Thank you.” The search for the suspect involved dogs, drones and scuba divers Officers used New York City’s muscular surveillance system . Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door to door looking for witnesses. When an arrest came five days later , those sprawling investigative efforts shared credit with an alert civilian’s instincts. A customer at a McDonald’s restaurant in Pennsylvania noticed another patron who resembled the man in the oblique security-camera photos New York police had publicized. Suspect is expected to be eventually be extradited to New York He remains jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. By late Monday evening, prosecutors in Manhattan had added a charge of murder, according to an online court docket. It’s unclear whether Luigi Nicholas Mangione has an attorney who can comment on the allegations. Asked at Monday’s arraignment whether he needed a public defender, Mangione asked whether he could “answer that at a future date.”
SAN JOSE, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nutanix, Inc. (“Nutanix”) (Nasdaq: NTNX), a leader in hybrid multicloud computing, today announced its intention to offer, subject to market conditions and other factors, $750 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Nutanix also expects to grant the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The notes will be unsecured senior obligations of Nutanix. Interest will be payable semi-annually in arrears. The notes will mature on December 15, 2029, unless earlier converted, redeemed, or repurchased. The notes will be convertible at the option of holders, subject to certain conditions and during certain periods. Upon conversion, the notes may be settled in cash, shares of Nutanix’s Class A common stock or a combination of cash and shares of Nutanix’s Class A common stock, at Nutanix’s election. The interest rate, initial conversion rate and other terms of the notes are to be determined at the time of the pricing of the offering. Nutanix intends to use the net proceeds from the offering to (i) repurchase a portion of its outstanding 0.25% Convertible Senior Notes due 2027 (the “2027 notes”) concurrently with the pricing of the offering in separate and privately negotiated transactions with certain holders of its 2027 notes (the “concurrent note repurchases”) effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix’s agent, and (ii) repurchase up to $200.0 million of shares of Nutanix’s Class A common stock in privately negotiated transactions with institutional investors effected through one of the initial purchasers of the notes or its affiliate, acting as Nutanix’s agent, at a price per share equal to the last reported sale price of Nutanix’s Class A common stock on the Nasdaq Global Select Market on the date of the pricing of the notes (the “Share Repurchase”). Any such Share Repurchase would not reduce the amount available for future repurchases under Nutanix’s existing share repurchase program. Nutanix intends to use the remaining net proceeds from the offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions. From time to time, Nutanix evaluates potential acquisitions of businesses, technologies or products. Currently, however, Nutanix does not have any understandings or agreements with respect to any acquisitions. The terms of the concurrent note repurchases are anticipated to be individually negotiated with each holder of the 2027 notes participating in the concurrent note repurchases, and will depend on several factors, including the market price of Nutanix’s Class A common stock and the trading price of the 2027 notes at the time of each such concurrent note repurchase. Certain holders of any 2027 notes that Nutanix agrees to repurchase may have hedged their equity price risk with respect to such 2027 notes and may, concurrently with the pricing of the notes, unwind all or part of their hedge positions by buying Nutanix’s Class A common stock and/or entering into or unwinding various derivative transactions with respect to Nutanix’s Class A common stock. Any repurchase of the 2027 notes, and the potential related market activities by holders of the 2027 notes participating in the concurrent note repurchases, together with the repurchase by Nutanix of any of its Class A common stock concurrently with the pricing of the notes, could increase (or reduce the size of any decrease in) the market price of Nutanix’s Class A common stock, which may affect the trading price of the notes at that time and the initial conversion price of the notes. Nutanix cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or its Class A common stock. No assurance can be given as to how much, if any, of the 2027 notes or the Class A common stock will be repurchased or the terms on which they will be repurchased. Neither the notes nor the shares of Nutanix’s Class A common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. About Nutanix Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify operations, freeing them to focus on their business outcomes. Building on its legacy as the pioneer of hyperconverged infrastructure, Nutanix is trusted by companies worldwide to power hybrid multicloud environments consistently, simply, and cost-effectively. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Nutanix’s financing plans, Nutanix’s ability to complete the offering, the timing and size of the offering, the concurrent note repurchases and the Share Repurchase, Nutanix’s intended use of the net proceeds of the offering. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether Nutanix will be able to consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions with respect to the offering of the notes, prevailing market conditions, the anticipated use of the net proceeds of the offering of the notes, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Forward-looking statements may be identified by the use of the words “may,” “will,” “expect,” “intend,” and other similar expressions. These forward-looking statements are based on estimates and assumptions by Nutanix’s management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. Actual results may differ materially from those anticipated or predicted by Nutanix’s forward-looking statements. All forward-looking statements are subject to other risks detailed in Nutanix’s Annual Report on Form 10-K for the fiscal year ended July 31, 2024, and the risks discussed in Nutanix’s other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Nutanix undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof, except as required by applicable law. © 2024 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. (“Nutanix”) in the United States and other countries. Other brand names or marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release is for informational purposes only and nothing herein constitutes a warranty or other binding commitment by Nutanix. Investor Contact: Richard Valera ir@nutanix.com Media Contact: Lia Bigano pr@nutanix.comHelp wanted: Cartwright school district needs more teachers
Felicity Curin, founder of the Montessori-inspired Little Kitchen Academy, told Fox News Digital why she believes interest in cooking with vegetables has grown since the COVID-19 pandemic. A Maryland mother said she's saving $1,800 a year by growing fruits and vegetables for her family – and she's paying it forward this Christmas by gifting homegrown presents from her garden. Christen McCoy, 39, grows over 50 types of plants in her backyard garden, including tomatoes, peppers, sprouts and pumpkins — saving herself and the family about $50 each week on groceries, news service SWNS reported. The Baltimore music teacher, wife and mother of three said she feeds her family these fruits and vegetables throughout the year – reducing the items she needs to buy at the grocery store. FAMILIES CAN SAVE $100 A MONTH ON FOOD BY DOING THIS: OREGON MOM "I save a lot of money in the winter months as I preserve the produce from earlier in the year," McCoy told SWNS. "In the summer months, I am able to grow strawberries and raspberries that my three young children will eat like oxygen." In a video recently posted on her Facebook page, McCoy provided an itemized list of the fruits and vegetables that have saved her cash. Christen McCoy (right) said she's saving her family $1,800 each year by growing her own fruits and vegetables in her backyard garden (left). (SWNS) McCoy claimed to have saved $230 on peppers; $205 on raspberries; $110 on strawberries, which she also uses in smoothies and to make jam; $80 on bush beans (she's got a freezer stocked with them); and $40 on herbs. McCoy only saved $30 in blueberries this year because her patch is still growing. EASIEST VEGETABLE STIR-FRY RECIPE EVER, SAYS FOUNDER OF LITTLE KITCHEN ACADEMY "But I know they'll pay off big time in the future," she said. "Tomatoes were the real money-maker," McCoy also said. "I saved $890." Among the vegetables grown in McCoy's garden: peppers, beans and tomatoes (shown above). (SWNS) One of her favorite dinners to cook from her garden, she said, is a one-pan meal made from peppers, onions, tomatoes, garlic and fresh herbs, paired with sausages and pasta , according to SWNS. "All my kids will gobble it up," she said. "It has so many fresh ingredients in there. Everything apart from my pasta and sausage is coming from my garden." CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER McCoy said that by harvesting her own fruits and vegetables, she educates her children about the process of growing food . "All my children are very active in the garden with me," she said. "It has had a huge impact on my family life, especially with my youngest. He is connecting everything he does with the science around growing things." McCoy says she saves money in the winter months by preserving the produce she harvested earlier in the year. (SWNS) This year, McCoy plans to gift family and friends some of her homegrown foods , including jars of jams and pepper jellies, which she told SWNS will save her $500 on gifts. For more Lifestyle articles, visit www.foxnews.com/lifestyle "I don't have to go to the store to buy them," she said. McCoy said her "gardening expenses are minimal." CLICK HERE TO GET THE FOX NEWS APP She added, "The flavor, the freshness and knowing exactly where your food comes from — you can't put a price on that." Fox News Digital reached out to McCoy for further comment. Peter Burke is a lifestyle editor with Fox News Digital.Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom's macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). "While iopofosine I 131's positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. "We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131's substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131's clinical success validates the platform's ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company's strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. "We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. "I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate TM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 [email protected] INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 [email protected]NEW YORK (AP) — The leaders of presidential campaign insist they simply didn’t have enough time to execute a winning strategy against , pointing to “ferocious” political headwinds that were ultimately too much to overcome in the 107-day period after . Harris’ leadership team, speaking on the “Pod Save America” podcast that aired on Tuesday, defended over the campaign’s closing days, some of which have faced scrutiny in the weeks since . Specifically, they defended Harris’ outreach to Republican voters, her from Biden, her silence on and her inability to schedule an interview with popular podcaster Joe Rogan. “In a 107-day race, it is very difficult to do all the things you would normally do in a year and a half, two years,” said Harris campaign senior adviser Jen O’Malley Dillon. David Plouffe, another senior adviser, added, “There was a price to be paid for the short campaign.” The pointed reflections on Harris’ loss came just before she was scheduled to host a conference call with supporters as the party begins a painful process of self-examination. Trump won every swing state and traditionally aligned with Democrats — young voters and voters of color, among them. Harris’ team did not question the legitimacy of Trump’s victory. “We lost,” O’Malley Dillon said. But none of the Harris’ advisers acknowledged any mistakes during the wide-ranging podcast interview hosted by former Democratic operatives. Instead, they indicated that Harris had few options given the compressed timeframe and the broad anti-incumbent headwinds that have challenged elected officials across the world. They also gave Trump’s team some credit. They specifically pointed to Trump’s closing attack ad, which highlighted Harris’ support for taxpayer-funded sex reassignment surgeries for transgender prisoners. “Obviously, it was a very effective ad at the end,” said Harris deputy campaign manager Quentin Fulks. “I think that it made her seem out of touch.” The campaign tested several potential response ads but, in the end, decided it was best to avoid a specific rebuttal. “There’s no easy answers to this,” O’Malley Dillon said. Plouffe said he thought the Trump attack ad against “Bidenomics” was even more effective, but he acknowledged that the transgender attacks were not helpful. “She was on tape,” he said. “Surgery for trans people who want to transition in prison was part of the Biden-Harris platform in 2020. It was part of what the administration did, right?” And while the campaign has faced lingering questions about its media strategy, Harris’ team said she actually wanted to participate in a podcast with Rogan, who is among the world’s most popular podcasters and ultimately endorsed Trump. Stephanie Cutter, another Harris senior adviser, said the campaign wasn’t able to “find a date” to make it work. “We had discussions with Joe Rogan’s team. They were great. They wanted us to come on. We wanted to come on,” she said. “Will she do it sometime in the future? Maybe. Who knows. But it didn’t ultimately impact the outcome one way or the other.” Plouffe noted that the campaign offered to do the Rogan podcast on the road in Austin, Texas. with Rogan in the podcaster’s studio. Harris’ campaign brass also defended her decision to court moderate Republicans in the campaign’s closing days. The decision has drawn ire from some progressives, who believe Harris should have worked harder to turn out more traditional Democratic voters. “This political environment sucked, OK? We were dealing with ferocious headwinds,” Plouffe said. “So we had a complicated puzzle to put together here in terms of the voters.” He acknowledged some “drift” toward Trump among non-college-educated voters, particularly voters of color, which made Harris’ outreach to moderate voters even more important. “Yes, of course you have to maximize your turnout and your vote share amongst liberal voters if you’re a Democrat. That was a huge focus,” he said. He added, “You’ve got to couple that with dominating in the middle. Not just winning it a little. We have to dominate the moderate vote.” Steve Peoples, The Associated Press
Ukraine is expanding its long-range arsenal for deep strikes inside RussiaThe best Black Friday deals under $50: Save up to 75% at Amazon, Walmart, Target, Our Place, Nordstrom and more
Plot thickens in Rs100 cr investment fraud
Manhattan police have obtained a warrant for the arrest of 26-year-old Luigi Nicholas Mangione , suspect in the killing of UnitedHealthcare CEO Brian Thompson . Mangione was arrested at a McDonald’s in Altoona, Pennsylvania, while carrying a gun, mask and writings linking him to the ambush. Mangione is being held without bail in Pennsylvania on charges of possession of an unlicensed firearm, forgery and providing false identification to police. Late Monday, Manhattan prosecutors charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Here's the latest: Luigi Nicholas Mangione, the suspect in the fatal shooting of a healthcare executive in New York City, apparently was living a charmed life: the grandson of a wealthy real estate developer, valedictorian of his elite Baltimore prep school and with degrees from one of the nation’s top private universities. Friends at an exclusive co-living space at the edge of touristy Waikiki in Hawaii where the 26-year-old Mangione once lived widely considered him a “great guy,” and pictures on his social media accounts show a fit, smiling, handsome young man on beaches and at parties. Now, investigators in New York and Pennsylvania are working to piece together why Mangione may have diverged from this path to make the violent and radical decision to gun down UnitedHealthcare CEO Brian Thompson in a brazen attack on a Manhattan street. The killing sparked widespread discussions about corporate greed, unfairness in the medical insurance industry and even inspired folk-hero sentiment toward his killer. ▶ Read more about Luigi Mangione Peter Weeks, the Blair County district attorney, says he’ll work with New York officials to try to return suspect Luigi Mangione there to face charges. Weeks said the New York charges are “more serious” than in Blair County. “We believe their charges take precedent,” Weeks said, promising to do what’s needed to accommodate New York’s prosecution first. Weeks spoke to reporters after a brief hearing at which a defense lawyer said Mangione will fight extradition. The defense asked for a hearing on the issue. In the meantime, Mangione will be detained at a state prison in western Pennsylvania. Manhattan District Attorney Alvin Bragg’s office said Tuesday it will seek a Governor’s warrant to secure Mangione’s extradition to Manhattan. Under state law, New York Gov. Kathy Hochul can issue a warrant of arrest demanding Mangione’s return to the state. Such a warrant must recite the facts necessary to the validity of its issuance and be sealed with the state seal. It would then be presented to law enforcement in Pennsylvania to expedite Mangione’s return to New York. But Blair County District Attorney Peter Weeks says it won’t be a substantial barrier to returning Mangione to New York. He noted that defendants contest extradition “all the time,” including in simple retail theft cases. Dickey, his defense lawyer, questioned whether the second-degree murder charge filed in New York might be eligible for bail under Pennsylvania law, but prosecutors raised concerns about both public safety and Mangione being a potential flight risk, and the judge denied it. Mangione will continue to be housed at a state prison in Huntingdon. He has 14 days to challenge the detention. Prosecutors, meanwhile, have a month to seek a governor’s warrant out of New York. Mangione, wearing an orange jumpsuit, mostly stared straight ahead at the hearing, occasionally consulting papers, rocking in his chair, or looking back at the gallery. At one point, he began to speak to respond to the court discussion, but was quieted by his lawyer. Luigi Mangione, 26, has also been denied bail at a brief court hearing in western Pennsylvania. He has 14 days to challenge the bail decision. That’s with some intervention from owner Elon Musk. The account, which hasn’t posted since June, was briefly suspended by X. But after a user inquired about it in a post Monday, Musk responded “This happened without my knowledge. Looking into it.” The account was later reinstated. Other social media companies such as Meta have removed his accounts. According to X rules, the platform removes “any accounts maintained by individual perpetrators of terrorist, violent extremist, or mass violent attacks, as well as any accounts glorifying the perpetrator(s), or dedicated to sharing manifestos and/or third party links where related content is hosted.” Mangione is not accused of perpetrating a terrorist or mass attack — he has been charged with murder — and his account doesn’t appear to share any writings about the case. He shouted something that was partly unintelligible, but referred to an “insult to the intelligence of the American people.” He’s there for an arraignment on local charges stemming from his arrest Monday. He was dressed in an orange jumpsuit as officers led him from a vehicle into the courthouse. Local defense lawyer Thomas Dickey is expected to represent the 26-year-old at a Tuesday afternoon hearing at the Blair County Courthouse. Dickey declined comment before the hearing. Mangione could have the Pennsylvania charges read aloud to him and may be asked to enter a plea. They include possession of an unlicensed firearm, forgery and providing false identification to police. In New York, he was charged late Monday with murder in the death of UnitedHealthcare’s CEO Brian Thompson. Mangione likely was motivated by his anger with what he called “parasitic” health insurance companies and a disdain with corporate greed, said a a law enforcement bulletin obtained by The Associated Press. He wrote that the U.S. has the most expensive healthcare system in the world and that the profits of major corporations continue to rise while “our life expectancy” does not, according to the bulletin, based on a review of the suspect’s hand-written notes and social media postings. He appeared to view the targeted killing of the UnitedHealthcare CEO as a symbolic takedown, asserting in his note that he is the “first to face it with such brutal honesty,” the bulletin said. Mangione called “Unabomber” Ted Kaczynski a “political revolutionary” and may have found inspiration from the man who carried out a series of bombings while railing against modern society and technology, the document said. A felony warrant filed in New York cites Altoona Officer Christy Wasser as saying she found the writings along with a semi-automatic pistol and an apparent silencer. The filing echoes earlier statements from NYPD Chief of Detectives Joseph Kenny who said Mangione had a three-page, handwritten document that shows “some ill will toward corporate America.” Mangione is now charged in Pennsylvania with being a fugitive of justice. A customer at the McDonald’s in Altoona, Pennsylvania, where Mangione was arrested said one of his friends had commented beforehand that the man looked like the suspect wanted for the shooting in New York City. “It started out almost a little bit like a joke, my one friend thought he looked like the shooter,” said the customer, who declined to give his full name, on Tuesday. “It wasn’t really a joke, but we laughed about it,” he added. The warrant on murder and other charges is a step that could help expedite his extradition from Pennsylvania. In court papers made public Tuesday, a New York City police detective reiterated key findings in the investigation he said tied Mangione to the killing, including surveillance footage and a fake ID he used to check into a Manhattan hostel on Nov. 24. Police officers in Altoona, Pennsylvania, found that ID when they arrested Mangione on Monday. Mangione is being held without bail in Pennsylvania on charges of possession of an unlicensed firearm, forgery and providing false identification to police. Late Monday, Manhattan prosecutors charged him with five counts, including murder, criminal possession of a weapon and criminal possession of a forged instrument. Mangione doesn’t yet have a lawyer who can speak on his behalf, court officials said. Images of Mangione released Tuesday by Pennsylvania State Police showed him pulling down his mask in the corner of the McDonald’s while holding what appeared to be hash browns and wearing a winter jacket and ski cap. In another photo from a holding cell, he stood unsmiling with rumpled hair. Mangione’s cousin, Maryland lawmaker Nino Mangione, announced Tuesday morning that he’s postponing a fundraiser planned later this week at the Hayfields Country Club north of Baltimore, which was purchased by the Mangione family in 1986. “Because of the nature of this terrible situation involving my Cousin I do not believe it is appropriate to hold my fundraising event scheduled for this Thursday at Hayfields,” Nino Mangione said in a social media post. “I want to thank you for your thoughts, prayers, and support. My family and I are heartbroken and ask that you remember the family of Mr. Thompson in your prayers. Thank you.” Officers used New York City’s muscular surveillance system . Investigators analyzed DNA samples, fingerprints and internet addresses. Police went door to door looking for witnesses. When an arrest came five days later , those sprawling investigative efforts shared credit with an alert civilian’s instincts. A customer at a McDonald’s restaurant in Pennsylvania noticed another patron who resembled the man in the oblique security-camera photos New York police had publicized. He remains jailed in Pennsylvania, where he was initially charged with possession of an unlicensed firearm, forgery and providing false identification to police. By late Monday evening, prosecutors in Manhattan had added a charge of murder, according to an online court docket. It’s unclear whether Luigi Nicholas Mangione has an attorney who can comment on the allegations. Asked at Monday’s arraignment whether he needed a public defender, Mangione asked whether he could “answer that at a future date.”'Thanks to him I...' Carlos Alcaraz shares the biggest learning experience he had watching Rafael Nadal over the yearsAsana stock price has suffered a harsh reversal in the past few days as investors fade the December 5 earnings surge. ASAN shares retreated to $21.65, down by over 22% from the highest point this month. Is this SaaS stock a good one to invest in? Advertisement Asana’s is a leader in its business Asana is a technology company offering thousands of companies solutions. Some of its top clients include Danone, Spotify, and Gannett. Advertisement According to Gartner, Asana is one of the industry leaders. Its top competitors include Smartsheet, Wrike, Monday, Airtable, Atlassian, and ClickUp. The collaboration industry has grown in the past few years as more companies have embraced remote work and technology. This means that the industry has a large total addressable market and strong competition. Asana’s business has grown well in the past few years, with revenue jumping from over $142 million in 2019 to over $706 million in the trailing twelve months. This growth happened as the number of core clients spending $5,000 a year rose to 23,609. Asana benefits from having thousands of customers and often experiencing low churn, meaning that its clients rarely move to competitors. The most recent results showed that its retention rate was about 98%, higher than most companies. The challenge, however, is that Asana’s business is slowing as competition rises. Signing up new large customers is also becoming difficult because they already have their providers. Asana’s slow growth and AI hopes Recent results showed that Asana’s revenue rose by 10% to $183 million. Analysts expect that Asana’s fourth-quarter revenues will come in at $188 million, up by about 9.9% from last year. This growth will bring its total annual revenue to $723 million, up by 10.8% from a year earlier. Asana’s revenue will then rise by in the next financial year. Its real numbers will likely be better than estimates because it has a long history of beating the consensus. Asana hopes that its AI solutions will help to supercharge its business trajectory. It has built AI Studio and Smart Workflows that are helping customers boost their productivity. Profitability has been another challenge as the company has continued to lose money in the past few years. Its cumulative net loss in the last five financial years stood at about $1 billion. Fortunately, it is now reducing its losses, with its Q3 loss at $60 million. Analysts see Asana’s loss per share narrowing from 14 cents this year to just 0.01 cents next year. There are concerns about Asana’s valuation. It has a market cap of over $4 billion and a rule of 40 metric of just 8%. This figure is calculated by adding the company’s profit margin and growth metric, and it is a sign that it prioritizes growth over profits. Read more: Asana stock price forecast A closer look at Asana’s weekly chart shows that it closely resembles most altcoins. It formed a double-bottom chart pattern at $11.33 and a neckline at $26. A double-bottom pattern often leads to a strong bullish breakout. Therefore, while Asana stock is highly overvalued, it will likely stage a strong comeback soon, especially if it continues to report strong results. If this happens, the next point to watch in 2025 will be the 38.2% Fibonacci Retracement level at $62.37, which is about 195% above the current level.
